Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness

Lance D. Miller, Jeff A. Chou, Michael A. Black, Cristin Print, Julia Chifman, Angela Alistar, Thomas Putti, Xiaobo Zhou, Davide Bedognetti, Wouter R. Hendrickx, Ashok Pullikuth, Jonathan Rennhack, Eran R. Andrechek, Sandra Demaria, Ena Wang, Francesco M. Marincola

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The abundance and functional orientation of tumor-infiltrating lymphocytes in breast cancer is associated with distant metastasis- free survival, yet how this association is influenced by tumor phenotypic heterogeneity is poorly understood. Here, a bioinformatics approach defined tumor biologic attributes that influence this association and delineated tumor subtypes that may differ in their ability to sustain durable antitumor immune responses. A large database of breast tumor expression profiles and associated clinical data was compiled, from which the ability of phenotypic markers to significantly influence the prognostic performance of a classification model that incorporates immune cell-specific gene signatures was ascertained. Markers of cell proliferation and intrinsic molecular subtype reproducibly distinguished two breast cancer subtypes that we refer to as immune benefit-enabled (IBE) and immune benefit-disabled (IBD). The IBE tumors, comprised mostly of highly proliferative tumors of the basal-like, HER2- enriched, and luminal B subtypes, could be stratified by the immune classifier into significantly different prognostic groups, while IBD tumors could not, indicating the potential for productive engagement of metastasis-protective immunity in IBE tumors, but not in IBD tumors. The prognostic stratification in IBE was independent of conventional variables. Gene network analysis predicted the activation of TNFa/IFNg signaling pathways in IBE tumors and the activation of the transforming growth factor-b pathway in IBD tumors. This prediction supports a model in which breast tumors can be distinguished on the basis of their potential for metastasis-protective immune responsiveness. Whether IBE and IBD represent clinically relevant contexts for evaluating sensitivity to immunotherapeutic agents warrants further investigation.

Original languageEnglish
Pages (from-to)600-610
Number of pages11
JournalCancer immunology research
Volume4
Issue number7
DOIs
Publication statusPublished - 1 Jul 2016

Fingerprint

Neoplasm Genes
Breast Neoplasms
Neoplasms
Neoplasm Metastasis
Activation Analysis
Tumor-Infiltrating Lymphocytes
Gene Regulatory Networks
Transforming Growth Factors
Computational Biology
Immunity
Cell Proliferation
Databases

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Miller, L. D., Chou, J. A., Black, M. A., Print, C., Chifman, J., Alistar, A., ... Marincola, F. M. (2016). Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Cancer immunology research, 4(7), 600-610. https://doi.org/10.1158/2326-6066.CIR-15-0149

Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. / Miller, Lance D.; Chou, Jeff A.; Black, Michael A.; Print, Cristin; Chifman, Julia; Alistar, Angela; Putti, Thomas; Zhou, Xiaobo; Bedognetti, Davide; Hendrickx, Wouter R.; Pullikuth, Ashok; Rennhack, Jonathan; Andrechek, Eran R.; Demaria, Sandra; Wang, Ena; Marincola, Francesco M.

In: Cancer immunology research, Vol. 4, No. 7, 01.07.2016, p. 600-610.

Research output: Contribution to journalArticle

Miller, LD, Chou, JA, Black, MA, Print, C, Chifman, J, Alistar, A, Putti, T, Zhou, X, Bedognetti, D, Hendrickx, WR, Pullikuth, A, Rennhack, J, Andrechek, ER, Demaria, S, Wang, E & Marincola, FM 2016, 'Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness', Cancer immunology research, vol. 4, no. 7, pp. 600-610. https://doi.org/10.1158/2326-6066.CIR-15-0149
Miller, Lance D. ; Chou, Jeff A. ; Black, Michael A. ; Print, Cristin ; Chifman, Julia ; Alistar, Angela ; Putti, Thomas ; Zhou, Xiaobo ; Bedognetti, Davide ; Hendrickx, Wouter R. ; Pullikuth, Ashok ; Rennhack, Jonathan ; Andrechek, Eran R. ; Demaria, Sandra ; Wang, Ena ; Marincola, Francesco M. / Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. In: Cancer immunology research. 2016 ; Vol. 4, No. 7. pp. 600-610.
@article{f5d9effa3df7432ebb53b17acc36d82c,
title = "Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness",
abstract = "The abundance and functional orientation of tumor-infiltrating lymphocytes in breast cancer is associated with distant metastasis- free survival, yet how this association is influenced by tumor phenotypic heterogeneity is poorly understood. Here, a bioinformatics approach defined tumor biologic attributes that influence this association and delineated tumor subtypes that may differ in their ability to sustain durable antitumor immune responses. A large database of breast tumor expression profiles and associated clinical data was compiled, from which the ability of phenotypic markers to significantly influence the prognostic performance of a classification model that incorporates immune cell-specific gene signatures was ascertained. Markers of cell proliferation and intrinsic molecular subtype reproducibly distinguished two breast cancer subtypes that we refer to as immune benefit-enabled (IBE) and immune benefit-disabled (IBD). The IBE tumors, comprised mostly of highly proliferative tumors of the basal-like, HER2- enriched, and luminal B subtypes, could be stratified by the immune classifier into significantly different prognostic groups, while IBD tumors could not, indicating the potential for productive engagement of metastasis-protective immunity in IBE tumors, but not in IBD tumors. The prognostic stratification in IBE was independent of conventional variables. Gene network analysis predicted the activation of TNFa/IFNg signaling pathways in IBE tumors and the activation of the transforming growth factor-b pathway in IBD tumors. This prediction supports a model in which breast tumors can be distinguished on the basis of their potential for metastasis-protective immune responsiveness. Whether IBE and IBD represent clinically relevant contexts for evaluating sensitivity to immunotherapeutic agents warrants further investigation.",
author = "Miller, {Lance D.} and Chou, {Jeff A.} and Black, {Michael A.} and Cristin Print and Julia Chifman and Angela Alistar and Thomas Putti and Xiaobo Zhou and Davide Bedognetti and Hendrickx, {Wouter R.} and Ashok Pullikuth and Jonathan Rennhack and Andrechek, {Eran R.} and Sandra Demaria and Ena Wang and Marincola, {Francesco M.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0149",
language = "English",
volume = "4",
pages = "600--610",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness

AU - Miller, Lance D.

AU - Chou, Jeff A.

AU - Black, Michael A.

AU - Print, Cristin

AU - Chifman, Julia

AU - Alistar, Angela

AU - Putti, Thomas

AU - Zhou, Xiaobo

AU - Bedognetti, Davide

AU - Hendrickx, Wouter R.

AU - Pullikuth, Ashok

AU - Rennhack, Jonathan

AU - Andrechek, Eran R.

AU - Demaria, Sandra

AU - Wang, Ena

AU - Marincola, Francesco M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The abundance and functional orientation of tumor-infiltrating lymphocytes in breast cancer is associated with distant metastasis- free survival, yet how this association is influenced by tumor phenotypic heterogeneity is poorly understood. Here, a bioinformatics approach defined tumor biologic attributes that influence this association and delineated tumor subtypes that may differ in their ability to sustain durable antitumor immune responses. A large database of breast tumor expression profiles and associated clinical data was compiled, from which the ability of phenotypic markers to significantly influence the prognostic performance of a classification model that incorporates immune cell-specific gene signatures was ascertained. Markers of cell proliferation and intrinsic molecular subtype reproducibly distinguished two breast cancer subtypes that we refer to as immune benefit-enabled (IBE) and immune benefit-disabled (IBD). The IBE tumors, comprised mostly of highly proliferative tumors of the basal-like, HER2- enriched, and luminal B subtypes, could be stratified by the immune classifier into significantly different prognostic groups, while IBD tumors could not, indicating the potential for productive engagement of metastasis-protective immunity in IBE tumors, but not in IBD tumors. The prognostic stratification in IBE was independent of conventional variables. Gene network analysis predicted the activation of TNFa/IFNg signaling pathways in IBE tumors and the activation of the transforming growth factor-b pathway in IBD tumors. This prediction supports a model in which breast tumors can be distinguished on the basis of their potential for metastasis-protective immune responsiveness. Whether IBE and IBD represent clinically relevant contexts for evaluating sensitivity to immunotherapeutic agents warrants further investigation.

AB - The abundance and functional orientation of tumor-infiltrating lymphocytes in breast cancer is associated with distant metastasis- free survival, yet how this association is influenced by tumor phenotypic heterogeneity is poorly understood. Here, a bioinformatics approach defined tumor biologic attributes that influence this association and delineated tumor subtypes that may differ in their ability to sustain durable antitumor immune responses. A large database of breast tumor expression profiles and associated clinical data was compiled, from which the ability of phenotypic markers to significantly influence the prognostic performance of a classification model that incorporates immune cell-specific gene signatures was ascertained. Markers of cell proliferation and intrinsic molecular subtype reproducibly distinguished two breast cancer subtypes that we refer to as immune benefit-enabled (IBE) and immune benefit-disabled (IBD). The IBE tumors, comprised mostly of highly proliferative tumors of the basal-like, HER2- enriched, and luminal B subtypes, could be stratified by the immune classifier into significantly different prognostic groups, while IBD tumors could not, indicating the potential for productive engagement of metastasis-protective immunity in IBE tumors, but not in IBD tumors. The prognostic stratification in IBE was independent of conventional variables. Gene network analysis predicted the activation of TNFa/IFNg signaling pathways in IBE tumors and the activation of the transforming growth factor-b pathway in IBD tumors. This prediction supports a model in which breast tumors can be distinguished on the basis of their potential for metastasis-protective immune responsiveness. Whether IBE and IBD represent clinically relevant contexts for evaluating sensitivity to immunotherapeutic agents warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84979753538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979753538&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0149

DO - 10.1158/2326-6066.CIR-15-0149

M3 - Article

VL - 4

SP - 600

EP - 610

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 7

ER -